Angiotensin (Ang) II stimulates hypertrophic growth of vascular smooth muscle cells (VSMC). Accompanying this growth is the induction of the expression of growth-related protooncogenes (c-fos, c-jun, and c-myc), as well as the synthesis of the autocrine growth factors, such as PDGF-A and TGF-,81. In this study, we demonstrate further that Ang II also induces the synthesis of basic fibroblast growth factor (bFGF), a potent mitogen for VSMC. To examine how these factors interact to modulate the growth response of VSMC to Ang II, we used antisense oligomers to determine the relative contribution of these three factors. Treatment of confluent, quiescent smooth muscle cells with specific antisense oligomers complementary to bFGF, PDGF-A, and TGF-#t1 efficiently inhibited the syntheses of these factors. Our results demonstrate that in these VSMC, TGF-,i1 affects a key antiproliferative action, modulating the mitogenic properties of bFGF. Autocrine PDGF exerts only a minimal effect on DNA synthesis. An imbalance in these signals activated by Ang II may result in abnormal VSMC growth leading to the development of vascular disease. (J. Clin. Invest.
Introduction
Abnormal growth of vascular smooth muscle cells (VSMC)' is central to the pathophysiology ofatherosclerosis, hypertension, and restenosis after angioplasty. In atherosclerosis, VSMC replication is one of the important events in atheroma formation ( 1 ) . In hypertension, medial hypertrophy occurs with endoreplication (polyploidy) in large conduit vessels and with true proliferation (hyperplasia) in the resistance vessels (2, 3) . Abnormal VSMC proliferation is responsible for the restenosis that develops at an alarming frequency after coronary and peripheral angioplasty, limiting the long-term efficacy of this procedure. The mechanisms responsible for this altered growth control are unknown, however, the expression ofautocrine growth factors such as PDGF, basic fibroblast growth factor (bFGF), and TGF-31 has been noted in vessels from hypertensive animals, atheromatous plaques from humans, and in injury-induced proliferation in rats (4) (5) (6) (7) (8) .
Multiple lines of evidence suggest that angiotensin (Ang) II plays a role in the regulation of VSMC proliferation. In vivo, angiotensin converting enzyme inhibitors block the abnormal vascular growth in response to hypertension and vascular injury (9) . Moreover, Ang II infusion induces vascular hypertrophy and proliferation in injured and uninjured vessels (10) . Using cultured VSMC, we and others have demonstrated that Ang II induces increases in RNA and protein synthesis with little or no increase in DNA synthesis (1 1-15) . Interestingly, Ang II exposure results in the increased expression of the protooncogenes, c-fos, c-jun, jun-B, and c-myc (16) (17) (18) . Furthermore, we have previously reported that in VSMC, Ang II increases the mRNA for PDGF A chain ( 18) and TGF-# I ( 19) .
Our previous studies ( 19) suggest that Ang II induces in cultured VSMC both a proliferative and antiproliferative pathway and the interaction ofthese two pathways is responsible for the nonmitogenic growth response to Ang II. Immunologic blockade of TGF-#31 resulted in an increase in DNA synthesis in response to Ang II, suggesting that TGF-fll mediated the antiproliferative pathway ( 19) . However, the identity of the factor(s) mediating the proliferative pathway is still unclear. While a role for PDGF-AA was possible, it is unlikely since we have shown that these cells are not very responsive to exogenously added PDGF-AA (Itoh et Figure 1 . Sequence of control and antisense oligonucleotides used in these studies.
X lo0-M), transferrin (5 qg/ml), and ascorbate (0.2 mM). This growth condition maintains smooth muscle cells in a quiescent, noncatabolic state and promotes the expression of smooth muscle cell-specific contractile proteins (20) . Synthesis and purification ofoligomers. Oligonucleotide sequences used in this study and their relationships to TGF-31, bFGF, and PDGF A chain mRNAs (21) (22) (23) are shown in Fig. 1 . Unmodified, 15-base deoxyribonucleotides were synthesized on an automated solid-phase synthesizer (Applied Biosystems Inc., Foster City, CA) using standard phosphoramide chemistry. Before use, the oligomers were purified by gel filtration, ethanol precipitated, lyophilized to dryness, and dissolved in the culture media. Antisense TGF, antisense FGF, and antisense PDGF oligonucleotides were complementary to human TGF-,B 1 mRNA, bFGF mRNA, and PDGF A chain mRNA, respectively, at the translation initiation region. Control oligonucleotides were either the sense oligonucleotide (sense TGF, sense FGF, and sense PDGF), or the oligonucleotide with the same oligonucleotide sequence but with a reversed 5'-3' orientation (reverse TGF, reverse FGF). To introduce the oligonucleotides into VSMC, a cationic liposome-mediated transfection method (lipofection) was used (24). Oligonucleotides dissolved in 50 ,l DSF media were mixed with LipofectinT Reagent DOTMA (NI l-(2,3 dioleyloxy) propyl]-N,N,N-trimethylammonium chloride) (BRL Life Technologies, Gaithersburg, MD) dissolved in the same volume of water in a ratio of 6:1 (wt/wt) and incubated for 30 min at room temperature. The oligonucleotides/liposome complex (100 gl) was then added dropwise to each well. In the experiments reported, the concentration of oligonucleotides was 5 ,M (25 ,g/ ml) .
Confirmation that the antisense oligomers blocked the synthesis of the specific growth factors was demonstrated by bioassay and is presented in Fig. 4 ( 19) . Bioassay for bFGF. Extraction of bFGF from VSMC and bioassay for bFGF activity using mouse 3T3 fibroblasts were performed as in a previous report (26) . Confluent quiescent rat VSMC ( 1.3 X 107) with or without previous treatment with antisense FGF/oligonucleotides were harvested from monolayer cultures by trypsinization, washed with PBS, and resuspended in 2 ml of 1 M NaCl/0.0I M Tris-HCl, pH 7.5, containing leupeptin (1 Ag/ml), pepstatin (4 AtM) and phenylmethylsulfonyl fluoride (1 mM). After cells were disrupted by three cycles of freezing and thawing followed by sonication for 1 min, the homogenate was centrifuged at 25,000 g for 30 min and the supernatant was dialyzed overnight against 0.1 M NaCl/0.01 M Tris-HCl, pH 7.5. All procedures were performed at 4°C, and aliquots ofcell extracts were stored at -80°C until use. In this study, the bFGF activity is expressed as bFGF antibody-inhibitable mitogenic activity. Therefore, for the measurement of bFGF activity, human bFGF standards (0.03-3 ng/ ml, Genzyme Corp., Boston, MA) or samples preincubated (2 h at 37°C) with either anti-bFGF IgG (R&D Systems) or nonimmune IgG at 10 pg/ ml were incubated with quiescent Swiss 3T3 cells for 20 h, after which the cells were pulse-labeled with 10 ,uCi/ml [3H ]thymidine for 8 h. For quantitation of the mitogenic activity in the cell extracts, the standard curve was plotted as counts per minute incorporated versus nanograms of bFGF. The antibody-inhibitable mitogenic activity (counts per minute) from the cell extracts was converted to nanograms of bFGF by comparison with the standard curve and was expressed as nanograms FGF per milligram protein extract.
Controls were performed to validate the use ofthe commercial antisera. Addition of nonimmune IgG had no effect on basal or bFGFstimulated thymidine incorporation into the test 3T3 cells, nor did the administration of anti-bFGF IgG affect basal thymidine incorporation into the 3T3 cells. Anti-bFGF IgG (10 ,ug/ ml) almost completely abolished the mitogenic activity of 1 ng/ml recombinant human bFGF without affecting the mitogenic activity of acidic FGF or PDGF. Serial dilution curves of cell extracts were parallel to the standard curve of bFGF.
Determination ofDNA synthesis. Relative rates of DNA and RNA syntheses were assessed by determination of tritiated thymidine ( 10 iCi/ml) and tritiated uridine (2 ACi/ml) incorporation respectively into TCA-precipitable material as previously reported ( 15 (Fig. 2 A) . Using the standard curve generated in Fig. 2 A, these levels of inhibition equated to 105±5 pg/ml of TGF-f 1 activity in the conditioned media from vehicle-treated VSMC, which increased 2.5-3-fold after Ang II exposure (273±38 pg/ml). The growth inhibitory activity in the conditioned media of the VSMC could be abolished by previous incubation of the conditioned media with a specific TGF-31 neutralizing antibody, demonstrating the specificity of this assay for TGF-31 ( 19) . VSMC synthesized bFGF basally and this production was stimulated by Ang II. We assayed bFGF activity in extracts of VSMC using Swiss 3T3 cells as bioassay. Antibody-inhibitable bFGF activity in VSMC extracts, as detected by the Swiss 3T3 cells bioassay, was increased threefold (Fig. 3) by Ang II. The basal and Ang II-induced expressions ofbFGF were confirmed by Northern blot analysis of bFGF mRNA (data not shown).
To examine the relative roles of these growth factors in Ang's growth effect, we synthesized antisense oligonucleotides (15 mer) complementary to human TGF-#31, bFGF, and PDGF A chain mRNAs (21-23) (Fig. 1) . Control oligonucleotides either in the sense orientation or the reversed sequence, were also synthesized. The oligonucleotides were introduced into VSMC by cationic liposome-mediated transfection (lipofection), as described previously (24). The optimal in vitro concentration of cationic liposome and its ratio to DNA that minimize cell toxicity and optimize DNA uptake were determined to be 2-4 ,ug/ml and 1:6 (wt/wt), respectively.
We next investigated the effect of the antisense oligomers on growth factor production. To examine the effectiveness of the blockade of TGF-,B1 production by the antisense oligonucleotide against TGF-j31 mRNA, we measured the amount of TGF-, I released by VSMC into the culture media again using 0 100 1000 bFGF (pg/ml) the mink lung epithelial cells bioassay (Fig. 4 A) (25) . Compared to the control oligomer, the antisense oligomer decreased the TGF-#3I activity in the conditioned media by -75%.
The antisense oligomer directed against FGF was similarly efficient (Fig. 4 B) as determined using the Swiss 3T3 bioassay. (28) . Fig. 5 demonstrates the effects of the antisense TGF-j31 oligonucleotide on DNA synthesis in basal and Ang Il-stimulated VSMC. TGF-f31 antisense oligomer (5 ,M) potentiated DNA synthesis by 35% in basal state, but more significantly in Ang II-stimulated state (87%, P < 0.05). In contrast, there was no change in the rate of DNA synthesis in Ang II-stimulated cells transfected with the control oligomer (Fig. 5 A) . These results indicate that TGF-4I exerts a tonic inhibitory action on VSMC proliferation and that in Ang II-stimulated state, it plays an even greater role in growth inhibition. These findings confirm our previous experiments using the anti-TGF-f3 1 neutralizing antibody, which resulted in a significant increase in cell number (50%) when these cells were stimulated with Ang 11 (19) .
We next addressed the mediator ofthe proliferative effect of Ang II. Antisense oligomer (5 puM) directed towards bFGF tended to suppress DNA synthesis in basal state, and inhibited this process significantly (by 30%) in Ang II-stimulated state (Fig. 5 B) . Thus, bFGF can act as a promoter ofVSMC proliferation especially in Ang Il-stimulated state. In contrast, antisense oligomers directed against PDGF-A had no effect on basal or Ang II-stimulated [3H]thymidine incorporation (data not shown). These results, therefore, indicate that Ang II activates a growth-stimulatory pathway mediated primarily by bFGF.
We examined the effect of simultaneous blockade of bFGF and TGF-j 1 production. The cotransfection of bFGF antisense oligomer with TGF-f 1 antisense oligomer almost completely abolished Ang II-induced VSMC proliferation that was unmasked by the blockade of TGF-41 production (Fig. 5 C) . In contrast, transfection of the antisense directed against PDGF-A had no effect on the DNA synthesis uncovered by the antisense oligomer directed against TGF-,B 1 (data not shown). Moreover, the neutralization of PDGF-AA activity by anti-PDGF-AA antibody was also ineffective at inhibiting this proliferative response (Table I ), suggesting that endogenous PDGF-AA plays an insignificant role in autocrine VSMC proliferation. This is also consistent with in vitro data that these cells express low levels of PDGF alpha receptors (29, 30).
To confirm further an interaction between TGF-O 1 and bFGF, we added these factors to confluent, quiescent VSMC either alone or in combination at levels that approximated that detected in the cells or conditioned media in response to Ang II (i.e., 100-500 pg/ml and 5 ng/ml, respectively, see Figs. 2 B  and 3 B) . The choice of bFGF concentration is difficult since endogenously produced bFGF is not secreted but remains cell associated, exerting its effects intracellularly or intranuclearly. Moreover, the endogenously produced TGF-,l1 may also act intracellularly since both the factor and its receptor are coexpressed in the same cells. Given these caveats, the results supported the overall hypothesis.
TGF-3 1 dose dependently decreased while bFGF increased DNA synthesis. The bFGF-induced DNA synthesis could be blocked by the addition of TGF-f1 (Fig. 6 A) . Thus, as has been demonstrated previously, TGF-, 1 exerts a potent antiproliferative effect on VSMC (31, 32) . Both TGF-, 1 and bFGF increased RNA synthesis. Interestingly, the effects of TGF-#31 and bFGF, when combined, appear additive (Fig. 6 B). Thus, taken together, these results demonstrate that TGFf 1 inhibits the proliferative effects of bFGF. pertrophy including an examination ofcell volume and protein content will be required to fully establish this point. Thus, taken together, these results suggest that the combined action of bFGF and TGF-j 1 mediated the growth effects of Ang II. bFGF is unique among peptide growth factors in that this protein is not secreted but remains associated with the cell or extracellular matrix (33) . Intracellularly, bFGF is associated with the nucleus, suggesting a nuclear site of action (34) . However, cell surface receptors are also present. In endothelial cells, bFGF has been implicated as an autocrine growth factor (27, 28). Moreover, transfection of 3T3 cells with a bFGF expression vector results in a cell line with enhanced proliferation (35) and migration (36) , indicating an autocrine or paracrine action of the expressed bFGF. However, the exact cellular site and mechanism of action are unclear.
Discussion
Several reports have described the opposing effects ofTGF-/1 and bFGF in cultured endothelial cells on proliferation, migration, and on urokinase and tissue type plasminogen activator production (37, 38) . This study is the first demonstration that these two growth factors counteract each other within the same cell population in an autocrine and/or intracrine fashion. Since bFGF is known to promote the production of plasminogen activator, which is crucial for the activation of TGF-31 (21, 22) , the interaction of these dual autocrine loops in the production and activation of these growth factors deserves further investigation. Parenthetically, we have demonstrated that in VSMC, bFGF enhanced TGF-/l mRNA expression (39 
